The UK's MHRA has approved Wegovy, the first GLP-1 receptor agonist tablet for weight loss, making the UK the third country to authorize the pills. This expands treatment options for adults with obesity or overweight with related health conditions.
The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
A pill version of the weight-loss drug Wegovy has been approved in the UK by the MHRA. Manufacturer Novo Nordisk states the once-daily tablet offers convenience over weekly injections and doesn't require refrigeration. Its availability on the NHS is pending expert assessment.
The UK has approved a pill version of the weight-loss drug Wegovy, manufactured by Novo Nordisk. This once-daily tablet, containing semaglutide, mimics a natural hormone to suppress appetite and slow digestion. While available via prescription from pharmacies soon, its NHS availability is pending expert assessment.
Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the US. The drug, approved for weight management and cardiovascular risk reduction, faces increasing competition in the growing obesity drug market.
Novo Nordisk has launched its weight loss pill Wegovy in the United Arab Emirates, marking its first expansion outside the U.S. market. The drug's approval by the Emirates Drug Establishment follows recent competition from Eli Lilly in the growing obesity drug sector.
Dezessete pessoas foram presas em Salvador em uma operação contra um grupo suspeito de roubo a farmácias, tráfico de drogas e armas, e lavagem de dinheiro. A ação também cumpre mandados no Rio de Janeiro e São Paulo, com bloqueio de bens de R$ 12,5 milhões.
Starting mid-June, France will reimburse 65% of Wegovy and Mounjaro obesity treatments for eligible patients. While patients report effectiveness, high costs and strict eligibility criteria, excluding those with IMC below 35 or 40 without comorbidities, are major concerns.
A new analysis shows semaglutide (Ozempic/Wegovy) slows kidney disease progression in type 2 diabetes patients, improving kidney function and survival rates, even with a history of cardiovascular events. The drug mimics GLP-1 hormones and is also popular for weight loss.
Medicamento para obesidade, semaglutida, chega ao Brasil com preço acessível. Versão nacional da EMS custará R$ 287 por mês na fase inicial, bem abaixo dos R$ 1 mil mensais anteriores.
La France va partiellement rembourser les traitements Wegovy et Mounjaro contre l'obésité et le surpoids, qui permettent une perte de poids jusqu'à 15%.
Retatrutide, a new obesity drug from Eli Lilly, has shown a 30% weight loss in trials, surpassing previous drugs like Ozempic. It mimics GLP-1 and other hormones, offering benefits beyond weight loss, including anti-inflammatory effects.
Retatrutide, a new obesity drug, has shown a 30% weight loss in trials, surpassing previous drugs. Experts highlight its broader benefits beyond weight loss, including reduced inflammation and improved cardiovascular and kidney function, attributing these to its multi-organ receptor action.
Experts suggest the rise of weight-loss drugs like Wegovy could influence future art, potentially popularizing a "GLP-1 face" characterized by rapid fat loss, similar to past aesthetic trends. This shift contrasts with historical art that often celebrated fuller figures.
Les médicaments anti-obésité Wegovy et Mounjaro, efficaces selon la Haute Autorité de santé, ne sont pas remboursés en France, laissant environ 10 millions de personnes en situation d'obésité à payer environ 300€ par mois. Les négociations entre les laboratoires et l'Etat sont bloquées depuis 1,5 ans.
The European Medicines Agency has recommended Novo Nordisk's Wegovy pill for adults with obesity or overweight conditions, potentially making it Europe's first oral weight-loss drug. Approved in the US in December 2025, the daily tablet offers an alternative to injectable versions.
A new study suggests GLP-1 drugs, known for weight loss and diabetes treatment, may slow the progression of certain obesity-related cancers. Comparing GLP-1 users to those on DPP-4 inhibitors, researchers found reduced cancer spread in lung, breast, colorectal, and liver cancers.
Novo Nordisk plans a major global push for its Wegovy weight-loss pill, aiming to expand beyond the U.S. market. The company's EVP, Emil Kongshøj Larsen, stated they will go "all in" on launches pending approvals, citing potential in patient interest and telehealth partnerships. This comes as Novo faces increasing competition from Eli Lilly's rival pill, Foundayo.
Hims & Hers' stock fell 13% after reporting a Q1 net loss of $92M, weak earnings guidance, and ongoing controversy over weight loss drug sales, despite a deal with Novo Nordisk.
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
Hims & Hers shares fell 15.5% in premarket trading after the company reported a $92 million first-quarter loss and provided earnings guidance that disappointed investors.
Hims & Hers shares fell in premarket trading after the company reported a $92 million first-quarter net loss and issued guidance that Citi described as mixed. Investors also focused on the firm's transition away from compounded GLP-1 sales.
India has become one of the first countries to introduce cheaper, generic brands of weight loss drugs like Ozempic and Wegovy, but health professionals warn a lack of regulation and oversight is causing problems.
